TIPS treatment for patients with cirrhosis and acute kidney injury

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness and safety of transjugular intrahepatic portosystemic shunt (TIPS) implantation in patients suffering from hepatorenal syndrome acute kidney injury (HRS-AKI) and liver cirrhosis, comparing it to standard therapy involving terlipressin and albumin. HRS-AKI is a severe condition that arises in patients with ascites, particularly those with portal hypertension. The study aims to determine if TIPS can provide better outcomes for these patients, who are at high risk for renal failure and liver transplantation. Participants will be monitored for their response to the intervention and any adverse effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with cirrhosis confirmed by histology or liver stiffness or with unequivocal signs in ultrasound, endoscopy and/or blood tests
2. Clinically evident ascites due to portal hypertension
3. HRS-AKI
4. Age: ≥ 18 to ≤ 80 years old at the time of consent
5. ECOG \< 4 prior to hospital admission
6. Subject has been informed of the nature of the study, is willing to comply with all required follow-up evaluations within the defined follow-up visit windows and has signed an Ethics Committee (EC) approved consent form.
7. Female subjects of childbearing potential have a negative pregnancy test ≤ 7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation. Female subjects will be exempted from this requirement in case they are sterile, infertile, or have been post-menopausal for at least 12 months (no menses). A contraceptive method with a pearl index below 1% is assumed to be effective.

Exclusion Criteria:

1. Recent or current use of nephrotoxic drugs (NSAIDS, Aminoglycosides or high-dosed iodinated contrast medium) in the previous 72 hours before AKI diagnosis
2. Improvement of renal function after 1 day of diuretic removal and plasma volume expansion with albumin 1-1.5 gr/kg
3. Uncontrolled shock within the last 48 hours prior to randomization
4. Patients with uncontrolled infection (defined by a 20 % increase in inflam-matory parameters (CRP, leucocytes or insufficient decrease of PMN in ascitic fluid \< 25 % from baseline in the case of a SBP) despite 48 hours of antibiotic treatment.
5. Patients with cardiac cirrhosis as defined by the development of cirrhosis in a patient with chronic heart failure due to a primary cardiac disease (is-chemic cardiomyopathy, hypertensive cardiomyopathy, etc.)
6. Patients with contraindications to TIPS placement (e.g. Bilirubin \> 85.5 µmol/L (≙ 5 mg/dL), recurrent hepatic encephalopathy, clinically relevant pulmonary hypertension, aortic stenosis)
7. Patients with cavernous portal vein thrombosis, splenic vein thrombosis or mesenteric vein thrombosis
8. Patients with clinically significant cardiac disease (NYHA ≥ II)
9. Patients with diastolic dysfunction grade 3.
10. Patients with a reduced systolic function with an ejection fraction ≤ 50 %
11. Patients with ACLF grade 3
12. Patients with creatinine value \> 442 µmol/L (≙ 5 mg/dL)
13. Patients with an acute variceal bleeding at the time of screening who have indication for pre-emptive TIPS and/or terlipressin.
14. Patients with refractory ascites as defined by the International Ascites Club (\< 800 gr weight loss over 4 days in patients on low salt diet and high dose diuretics (spironolactone 400 mg /day and furosemide \* 160 mg /day), or lower dose of diuretics with complications secondary to the use of diuretics such as hyponatremia, renal failure, hepatic encephalopathy. \*equivalent dose of torasemide 40 mg/day
15. Patients with hepatocellular carcinoma outside of the Milan criteria
16. Patients with hepatocellular carcinoma within the Milan criteria in whom the tumor is located in the puncture tract.
17. Patients with benign liver tumors (except regenerative nodules) which are located in the puncture tract.
18. Patients who already have a TIPS placed
19. Patients who already had a liver transplantation
20. Patients with other comorbidities that lead to an estimated life expectancy under 1 year.
21. Patients with respiratory insufficiency which requires mechanical ventila-tion
22. Patients with circulatory failure which requires administration of other vas-opressors (catecholamines)
23. Patients receiving renal replacement therapy
24. The subject is currently enrolled in another investigational device or drug trial.
25. Patients with pregnancy or lactation
26. Patients which are suspected to be incompliant for study participation.

Where it's running

• University Hospital RWTH Aachen
  Aachen, Germany Recruiting
• University Hospital Dresden, Medical Clinic I, Gastroenterology
  Dresden, Germany Recruiting
• University Hospital Freiburg
  Freiburg im Breisgau, Germany Recruiting
• University Hospital Halle
  Halle, Germany Recruiting
• University Hospital Hamburg-Eppendorf
  Hamburg, Germany Recruiting
• Medical University Hannover
  Hanover, Germany Recruiting

Study contacts

• Study coordinator: Cristina Ripoll, Prof. Dr.
• Email: cristina.ripoll@med.uni-jena.de
• Phone: +4936419

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating fluid treatment strategies for kidney injury in cirrhosis patients

  This study is testing two different ways to give IV fluids to people with kidney injury and cirrhosis to see which method helps them feel better and survive longer.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT06525623

• Carvedilol plus simvastatin versus carvedilol alone for cirrhosis-related heart dysfunction

  This trial will test whether adding simvastatin to carvedilol helps adults with cirrhosis and cirrhotic cardiomyopathy reduce liver decompensation and improve survival.

  Recruiting Post Graduate Institute of Medical Education and Research, Chandigarh · Chandigarh · NCT06431919

• Evaluating PHIN-214 for treating liver cirrhosis

  This study is testing a new treatment called PHIN-214 to see if it can safely help people with liver cirrhosis improve their liver function and manage related health issues.

  Recruiting at 9 sites Phase 1 PharmaIN · Chandler, Arizona and 8 other locations · NCT05490888

• Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery

  This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07888634

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Biomarkers to predict CSA-AKI risk before heart surgery

  This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07811570

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.